1 Study Coverage
    1.1 Human Immumoglobulin (PH4) for Intravenous Injection Product Introduction
    1.2 Market by Type
        1.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 1g/20ml
        1.2.3 1.25g/25ml
        1.2.4 2.5g/50ml
        1.2.5 5g/100ml
        1.2.6 10g/200ml
    1.3 Market by Application
        1.3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Estimates and Forecasts 2017-2028
    2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Estimates and Forecasts 2017-2028
    2.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region
        2.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2017-2022)
        2.4.2 Global Sales Human Immumoglobulin (PH4) for Intravenous Injection by Region (2023-2028)
    2.5 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region
        2.5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2017-2022)
        2.5.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Manufacturers
        3.1.1 Global Top Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers by Sales (2017-2022)
        3.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection in 2021
    3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturers
        3.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturers (2017-2022)
        3.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Human Immumoglobulin (PH4) for Intravenous Injection Revenue in 2021
    3.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type
        4.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Historical Sales by Type (2017-2022)
        4.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecasted Sales by Type (2023-2028)
        4.1.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type
        4.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Historical Revenue by Type (2017-2022)
        4.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Type
        4.3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Type (2017-2022)
        4.3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application
        5.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Historical Sales by Application (2017-2022)
        5.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecasted Sales by Application (2023-2028)
        5.1.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    5.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application
        5.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Historical Revenue by Application (2017-2022)
        5.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    5.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Application
        5.3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Application (2017-2022)
        5.3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Type
        6.1.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028)
        6.1.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2028)
    6.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Application
        6.2.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028)
        6.2.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2028)
    6.3 North America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
        6.3.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2028)
        6.3.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Type
        7.1.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028)
        7.1.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2028)
    7.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Application
        7.2.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028)
        7.2.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2028)
    7.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
        7.3.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2028)
        7.3.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Type
        8.1.1 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028)
        8.1.2 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2028)
    8.2 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Application
        8.2.1 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028)
        8.2.2 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2028)
    8.3 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region
        8.3.1 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2017-2028)
        8.3.2 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Type
        9.1.1 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028)
        9.1.2 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2028)
    9.2 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Application
        9.2.1 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028)
        9.2.2 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2028)
    9.3 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
        9.3.1 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2028)
        9.3.2 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Type
        10.1.1 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2028)
    10.2 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Application
        10.2.1 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2028)
    10.3 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country
        10.3.1 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Boya-Bio
        11.1.1 Boya-Bio Corporation Information
        11.1.2 Boya-Bio Overview
        11.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Boya-Bio Recent Developments
    11.2 Beijing Tiantan Biological Products
        11.2.1 Beijing Tiantan Biological Products Corporation Information
        11.2.2 Beijing Tiantan Biological Products Overview
        11.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Beijing Tiantan Biological Products Recent Developments
    11.3 Guangdong Shuagnlin Bio-pharmacy
        11.3.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
        11.3.2 Guangdong Shuagnlin Bio-pharmacy Overview
        11.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
    11.4 Weiguang Biological
        11.4.1 Weiguang Biological Corporation Information
        11.4.2 Weiguang Biological Overview
        11.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Weiguang Biological Recent Developments
    11.5 Hualan Bio
        11.5.1 Hualan Bio Corporation Information
        11.5.2 Hualan Bio Overview
        11.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Hualan Bio Recent Developments
    11.6 CTBB
        11.6.1 CTBB Corporation Information
        11.6.2 CTBB Overview
        11.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 CTBB Recent Developments
    11.7 Sinopharm
        11.7.1 Sinopharm Corporation Information
        11.7.2 Sinopharm Overview
        11.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Sinopharm Recent Developments
    11.8 Nanyue Biopharming
        11.8.1 Nanyue Biopharming Corporation Information
        11.8.2 Nanyue Biopharming Overview
        11.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Nanyue Biopharming Recent Developments
    11.9 Shanghai RAAS
        11.9.1 Shanghai RAAS Corporation Information
        11.9.2 Shanghai RAAS Overview
        11.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Shanghai RAAS Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Human Immumoglobulin (PH4) for Intravenous Injection Industry Chain Analysis
    12.2 Human Immumoglobulin (PH4) for Intravenous Injection Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Human Immumoglobulin (PH4) for Intravenous Injection Production Mode & Process
    12.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales and Marketing
        12.4.1 Human Immumoglobulin (PH4) for Intravenous Injection Sales Channels
        12.4.2 Human Immumoglobulin (PH4) for Intravenous Injection Distributors
    12.5 Human Immumoglobulin (PH4) for Intravenous Injection Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Human Immumoglobulin (PH4) for Intravenous Injection Industry Trends
    13.2 Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
    13.3 Human Immumoglobulin (PH4) for Intravenous Injection Market Challenges
    13.4 Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
14 Key Findings in The Global Human Immumoglobulin (PH4) for Intravenous Injection Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of 1g/20ml
    Table 3. Major Manufacturers of 1.25g/25ml
    Table 4. Major Manufacturers of 2.5g/50ml
    Table 5. Major Manufacturers of 5g/100ml
    Table 6. Major Manufacturers of 10g/200ml
    Table 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2017-2022) & (K Units)
    Table 10. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2017-2022)
    Table 11. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2023-2028) & (K Units)
    Table 12. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2023-2028)
    Table 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2017-2022) & (US$ Million)
    Table 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2017-2022)
    Table 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2023-2028) & (US$ Million)
    Table 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2023-2028)
    Table 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Manufacturers (2017-2022) & (K Units)
    Table 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Manufacturers (2017-2022)
    Table 19. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 20. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Manufacturers (2017-2022)
    Table 21. Human Immumoglobulin (PH4) for Intravenous Injection Price by Manufacturers (2017-2022) &(US$/Unit)
    Table 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Human Immumoglobulin (PH4) for Intravenous Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immumoglobulin (PH4) for Intravenous Injection as of 2021)
    Table 24. Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base Distribution and Headquarters
    Table 25. Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Product Offered
    Table 26. Date of Manufacturers Enter into Human Immumoglobulin (PH4) for Intravenous Injection Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2022) & (K Units)
    Table 29. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2023-2028) & (K Units)
    Table 30. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Type (2017-2022)
    Table 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Type (2023-2028)
    Table 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2022) & (US$ Million)
    Table 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2023-2028) & (US$ Million)
    Table 34. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Type (2017-2022)
    Table 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Type (2023-2028)
    Table 36. Human Immumoglobulin (PH4) for Intravenous Injection Price by Type (2017-2022) & (US$/Unit)
    Table 37. Global Human Immumoglobulin (PH4) for Intravenous Injection Price Forecast by Type (2023-2028) & (US$/Unit)
    Table 38. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2022) & (K Units)
    Table 39. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2023-2028) & (K Units)
    Table 40. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Application (2017-2022)
    Table 41. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Application (2023-2028)
    Table 42. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2022) & (US$ Million)
    Table 43. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2023-2028) & (US$ Million)
    Table 44. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Application (2017-2022)
    Table 45. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Application (2023-2028)
    Table 46. Human Immumoglobulin (PH4) for Intravenous Injection Price by Application (2017-2022) & (US$/Unit)
    Table 47. Global Human Immumoglobulin (PH4) for Intravenous Injection Price Forecast by Application (2023-2028) & (US$/Unit)
    Table 48. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2022) & (K Units)
    Table 49. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2023-2028) & (K Units)
    Table 50. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2022) & (US$ Million)
    Table 51. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2023-2028) & (US$ Million)
    Table 52. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2022) & (K Units)
    Table 53. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2023-2028) & (K Units)
    Table 54. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2022) & (US$ Million)
    Table 55. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2023-2028) & (US$ Million)
    Table 56. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2022) & (K Units)
    Table 57. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2023-2028) & (K Units)
    Table 58. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2022) & (US$ Million)
    Table 59. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2023-2028) & (US$ Million)
    Table 60. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2022) & (K Units)
    Table 61. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2023-2028) & (K Units)
    Table 62. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2022) & (US$ Million)
    Table 63. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2023-2028) & (US$ Million)
    Table 64. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2022) & (K Units)
    Table 65. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2023-2028) & (K Units)
    Table 66. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2022) & (US$ Million)
    Table 67. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2023-2028) & (US$ Million)
    Table 68. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2022) & (K Units)
    Table 69. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2023-2028) & (K Units)
    Table 70. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2022) & (US$ Million)
    Table 71. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2023-2028) & (US$ Million)
    Table 72. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2022) & (K Units)
    Table 73. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2023-2028) & (K Units)
    Table 74. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2022) & (US$ Million)
    Table 75. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2023-2028) & (US$ Million)
    Table 76. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2022) & (K Units)
    Table 77. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2023-2028) & (K Units)
    Table 78. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2022) & (US$ Million)
    Table 79. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2023-2028) & (US$ Million)
    Table 80. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2017-2022) & (K Units)
    Table 81. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2023-2028) & (K Units)
    Table 82. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2017-2022) & (US$ Million)
    Table 83. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2023-2028) & (US$ Million)
    Table 84. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2022) & (K Units)
    Table 85. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2023-2028) & (K Units)
    Table 86. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2022) & (US$ Million)
    Table 87. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2023-2028) & (US$ Million)
    Table 88. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2022) & (K Units)
    Table 89. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2023-2028) & (K Units)
    Table 90. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2022) & (US$ Million)
    Table 91. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2023-2028) & (US$ Million)
    Table 92. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2022) & (K Units)
    Table 93. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2023-2028) & (K Units)
    Table 94. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2022) & (US$ Million)
    Table 95. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2023-2028) & (US$ Million)
    Table 96. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2022) & (K Units)
    Table 97. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2023-2028) & (K Units)
    Table 98. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2017-2022) & (US$ Million)
    Table 99. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Type (2023-2028) & (US$ Million)
    Table 100. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2022) & (K Units)
    Table 101. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2023-2028) & (K Units)
    Table 102. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2017-2022) & (US$ Million)
    Table 103. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2023-2028) & (US$ Million)
    Table 104. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2017-2022) & (K Units)
    Table 105. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2023-2028) & (K Units)
    Table 106. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2017-2022) & (US$ Million)
    Table 107. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2023-2028) & (US$ Million)
    Table 108. Boya-Bio Corporation Information
    Table 109. Boya-Bio Description and Major Businesses
    Table 110. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 111. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. Boya-Bio Recent Developments
    Table 113. Beijing Tiantan Biological Products Corporation Information
    Table 114. Beijing Tiantan Biological Products Description and Major Businesses
    Table 115. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 116. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. Beijing Tiantan Biological Products Recent Developments
    Table 118. Guangdong Shuagnlin Bio-pharmacy Corporation Information
    Table 119. Guangdong Shuagnlin Bio-pharmacy Description and Major Businesses
    Table 120. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 121. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Guangdong Shuagnlin Bio-pharmacy Recent Developments
    Table 123. Weiguang Biological Corporation Information
    Table 124. Weiguang Biological Description and Major Businesses
    Table 125. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 126. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. Weiguang Biological Recent Developments
    Table 128. Hualan Bio Corporation Information
    Table 129. Hualan Bio Description and Major Businesses
    Table 130. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 131. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Hualan Bio Recent Developments
    Table 133. CTBB Corporation Information
    Table 134. CTBB Description and Major Businesses
    Table 135. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 136. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. CTBB Recent Developments
    Table 138. Sinopharm Corporation Information
    Table 139. Sinopharm Description and Major Businesses
    Table 140. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 141. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. Sinopharm Recent Developments
    Table 143. Nanyue Biopharming Corporation Information
    Table 144. Nanyue Biopharming Description and Major Businesses
    Table 145. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 146. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. Nanyue Biopharming Recent Developments
    Table 148. Shanghai RAAS Corporation Information
    Table 149. Shanghai RAAS Description and Major Businesses
    Table 150. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 151. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product Model Numbers, Pictures, Descriptions and Specifications
    Table 152. Shanghai RAAS Recent Developments
    Table 153. Key Raw Materials Lists
    Table 154. Raw Materials Key Suppliers Lists
    Table 155. Human Immumoglobulin (PH4) for Intravenous Injection Distributors List
    Table 156. Human Immumoglobulin (PH4) for Intravenous Injection Customers List
    Table 157. Human Immumoglobulin (PH4) for Intravenous Injection Market Trends
    Table 158. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
    Table 159. Human Immumoglobulin (PH4) for Intravenous Injection Market Challenges
    Table 160. Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
    Table 161. Research Programs/Design for This Report
    Table 162. Key Data Information from Secondary Sources
    Table 163. Key Data Information from Primary Sources
List of Figures
    Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Product Picture
    Figure 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Type in 2021 & 2028
    Figure 3. 1g/20ml Product Picture
    Figure 4. 1.25g/25ml Product Picture
    Figure 5. 2.5g/50ml Product Picture
    Figure 6. 5g/100ml Product Picture
    Figure 7. 10g/200ml Product Picture
    Figure 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Application in 2021 & 2028
    Figure 9. Hospital
    Figure 10. Clinic
    Figure 11. Others
    Figure 12. Human Immumoglobulin (PH4) for Intravenous Injection Report Years Considered
    Figure 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales 2017-2028 (K Units)
    Figure 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2017-2028 (US$ Million)
    Figure 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2017-2022)
    Figure 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2023-2028)
    Figure 19. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales YoY (2017-2028) & (K Units)
    Figure 20. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales YoY (2017-2028) & (K Units)
    Figure 22. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales YoY (2017-2028) & (K Units)
    Figure 24. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales YoY (2017-2028) & (K Units)
    Figure 26. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales YoY (2017-2028) & (K Units)
    Figure 28. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue YoY (2017-2028) & (US$ Million)
    Figure 29. The Human Immumoglobulin (PH4) for Intravenous Injection Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 30. The Top 5 and 10 Largest Manufacturers of Human Immumoglobulin (PH4) for Intravenous Injection in the World: Market Share by Human Immumoglobulin (PH4) for Intravenous Injection Revenue in 2021
    Figure 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    Figure 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    Figure 34. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    Figure 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    Figure 36. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    Figure 37. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    Figure 38. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    Figure 39. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    Figure 40. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Country (2017-2028)
    Figure 41. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Country (2017-2028)
    Figure 42. U.S. Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 43. Canada Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 44. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    Figure 45. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    Figure 46. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    Figure 47. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    Figure 48. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Country (2017-2028)
    Figure 49. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Country (2017-2028)
    Figure 50. Germany Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 51. France Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 52. U.K. Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 53. Italy Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 54. Russia Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 55. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Region (2017-2028)
    Figure 60. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Region (2017-2028)
    Figure 61. China Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 62. Japan Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 63. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 64. India Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 65. Australia Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 66. Taiwan Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 67. Indonesia Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 68. Thailand Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 69. Malaysia Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 70. Philippines Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 71. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    Figure 72. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    Figure 73. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    Figure 74. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    Figure 75. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Country (2017-2028)
    Figure 76. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Country (2017-2028)
    Figure 77. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 78. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 79. Argentina Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 80. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2017-2028)
    Figure 81. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2017-2028)
    Figure 83. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Country (2017-2028)
    Figure 85. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Country (2017-2028)
    Figure 86. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 87. Saudi Arabia Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 88. UAE Human Immumoglobulin (PH4) for Intravenous Injection Revenue (2017-2028) & (US$ Million)
    Figure 89. Human Immumoglobulin (PH4) for Intravenous Injection Value Chain
    Figure 90. Human Immumoglobulin (PH4) for Intravenous Injection Production Process
    Figure 91. Channels of Distribution
    Figure 92. Distributors Profiles
    Figure 93. Bottom-up and Top-down Approaches for This Report
    Figure 94. Data Triangulation
    Figure 95. Key Executives Interviewed